Dr. Fuhrman’s Protocol for Treating Parkinson’s

By Joel Fuhrman, M.D. www.drfuhrman.com

Powerful, Risk-Free Steps You Can Take For Yourself!

My protocol for treating Parkinson’s disease (PD) can be summarized as follows:

Use Less Medication.

Decreasing the dosage of PD medications, particularly levodopa, lessens the probability of side effects, including dyskinesia. Delaying the use of levodopa is also beneficial, as duration is also a risk factor for levodopa-induced dyskinesia. When medication is needed, I recommend using a much lower dose. When combined with the dietary and supplemental protocol below, less medication is required to control troubling symptoms.

Eat A Lower Protein Diet That Is High In Vegetables.

High-protein diets can interfere with the levodopa availability, leading to a reduced efficacy of the drug.2,40 This occurs because certain amino acids compete with levodopa for absorption, both in the intestinal wall and the blood-brain barrier.41 Several clinical studies have shown that consuming a low-protein diet, especially in the daytime, improves the movement symptoms of PD.42,43,40,44,45 This is especially beneficial in those patients who have fluctuations in their response to levodopa; these patients become more sensitive to levodopa and receive more consistent benefits from the drug.46

A plant-based diet also can decrease the needed dose of levodopa, 25 which is beneficial because a lower dose of levodopa decreases the potential for dyskinesia. A large amount of vegetables, in addition to the micronutrient and antioxidant content, also provides much needed fiber and water to PD patients, 60-80 percent of whom suffer from constipation.2,47

Avocado, nuts and seeds, and green vegetables are rich sources of glutathione, an important antioxidant molecule in the brain.

In addition to adopting a nutritarian diet, I also recommend taking the following supplements:

DHA supplementation:  400 mg per day, or as indicated by blood tests;

GLA supplementation, usually with borage oil:  240 mg daily;

Glutathione:  100 mg twice daily;

Alpha-lipoic acid:   100 mg twice daily;

Co Q10:   50 mg twice daily;

Acetyl-L-carnitine:   50 mg twice daily;

Grape seed extract:  10 mg twice daily.

References

1. MedlinePlus: Parkinson’s Disease http://www.nlm.nih.gov/medlineplus/parkinsonsdisease. html

2. Parkinson’s Disease Foundation http://www.pdf.org

3. Brown TP, et al. Pesticides and Parkinson’s Disease—Is There a Link? Environ Health Perspect 114:156-164 (2006).

4. Priyadarshi A, et al. A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 2000 Aug;21(4):435-40.

5. Dinis-Oliveira RJ, et al. Paraquat exposure as an etiological factor of Parkinson’s disease. Neurotoxicology 2006 Dec;27(6):1110-22. [Epub 2006 Jul 3.]

6. United States Environmental Protection Agency. Prevention, Pesticides, and Toxic Substances (7508W) EPA-738-F-96-018 August 1997 R.E.D. FACTS Paraquat Dichloride.

7. Uversky VN, et al. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett 2001 Jul 6;500 (3):105-8.

8. http://www.nysaes.cornell.edu/pp/resourceguide/mfs/11rotenone.php

9. Elbaz A, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009 Apr 13;66(4):494-504. [Epub ahead of print.]

10. United States Center for Disease Control Third National Report on Human Exposure to Environmental Chemicals: Organochlorine Pesticides.

11. Fleming L.Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol 1994 Jul;36(1):100-3.

12. United States Center for Disease Control Factsheet: Dieldrin.

13. Kanthasamy AG, et al. Dieldrin-induced neurotoxicity: relevance to Parkinson’s disease pathogenesis. Neurotoxicology 2005 Aug;26(4):701-19.

14. Richardson JR. Elevated serum pesticide levels and risk of Parkinson disease. Arch Neurol 2009 Jul;66(7):870-5.

15. Karen DJ, et al. Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology 2001 Dec;22(6):811-7.

16. National Pesticides Telecommunication Network—Permethrin.

17. http://www.epa.gov/oecaagct/torg.html

18. Calon F, Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 2007;77(5-6):287-93.

19. Bousquet M, et al. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. The FASEB Journal 2008;22:1213-1225.

20. Samadi P, et al. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 2006;59(2): 282-8.

21. National Parkinson Foundation http://www.parkinson.org/Page.aspx?pid=227

22. Encarnacion EV, et al. Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments. Eur Neurol 2008;60:57-66.

23. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 1997 Dec;25(3):335-58.

24. Sullivan PG, Brown MR. Mitochondrial aging and dysfunction in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2005 Mar;29(3):407-10.

25. Kidd PM. Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 2000 Dec;5(6):502-29.

26. Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev 2005 Dec;10(4):268-93.

27. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res 2008 Jan;33(1):194-203. [Epub 2007 Jun 29.]

28. Packer L, et al. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22(1-2):359-78.

29. Maczurek A, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev 2008 Oct-Nov;60(13-14): 1463-70. Epub 2008 Jul 4.

30. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008 Nov;66(11):646-57.

31. Zhang H, et al. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease. J Cell Mol Med 2008 Jun. [Epub ahead of print.]

32. Karunakaran S, et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson’s disease: protection by alpha-lipoic acid. FASEB J 2007 Jul;21(9):2226-36. [Epub 2007 Mar 16.]

33. Puca FM, et al. Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson’s disease. Int J Clin Pharmacol Res 1990;10(1-2):139-43.

34. Montgomery SA, et al. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 2003; 18:61-71.

35. Shults CW, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002 Oct;59(10):1541-50.

36. Growdon JH, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci 1982 Mar 8; 30(10):827-32.

37. Lemoine P, et al. L-tyrosine: a long term treatment of Parkinson’s disease. C R Acad Sci III 1989;309(2):43-7.

38. Youdim KA, et al. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000 Jul-Aug;18(4-5):383-99.

39. De Franceschi, et al. Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid. J Mol Biol 2009 Nov 20;394(1):94-107. [Epub 2009 Sep 8.]

40. Barichella M. Major nutritional issues in the management of Parkinson’s disease. Mov Disord 2009 Oct 15;24(13):1881-92.

41. Håglin L, Selander B. Diet in Parkinson disease. Tidsskr Nor Laegeforen 2000 Feb 20;120(5):576-8.

42. Riley D, et al. Practical application of a low-protein diet for Parkinson’s disease. Neurology 1988 Jul;38(7):1026-31.

43. Tsui JK, et al. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology 1989 Apr;39(4):549-52.

44. Bracco F, et al. Protein redistribution diet and antiparkinsonian response to levodopa. Eur Neurol 1991;31(2):68-71.

45. Karstaedt PJ, et al. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992 Feb;49(2):149-51.

46. Hirata H, et al. Influence of protein-restricted diet on motor response fluctuations in Parkinson’s disease. Rinsho Shinkeigaku 1992 Sep;32(9):973-8.

47. Ueki A, et al. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J Neurol 2004 Oct;251 Suppl 7:vII18-23.

48. Gao X, et al. Prospective study of dietary pattern and risk of Parkinson Disease. Am J Clin Nutr 2007 November;86(5):1486-1494.

49. Johnson CC, et al. Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol 1999 Dec;28(6):1102-9.

50. Chen H, et al. Dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007 May 1;165(9):998-1006.

51. Perez CA, et al. Iron Chelators as Potential Therapeutic Agents for Parkinson’s Disease. Curr Bioact Compd 2008 Oct 1;4(3):150-158.

52. Fillit H. Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol 2006;97(8)1262-5.

53. Notkola I, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allela, and Alzheimer’s disease. Neuroepidemiology 1998;17:14-20.

54. Scarmeas N, et al. Mediterranean diet, Alzheimer’s disease, and vascular mediation. Arch Neurol 2006;63:1709-17.

55. Morris MC, et al. Dietary fats and the risk of incident Alzheimer’s disease. Arch Neurol 2003;60:194-200.

56. Morris MC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006;63:1085-8.

57. Puglielli L, et al. Alzheimer’s disease B-amyloid activity mimics cholesterol oxidase. J Clin Invest 2005;115:2556-63. University of Rochester Medical Center (2007, November 8). Copper Damages Protein That Defends Against Alzheimer’s. ScienceDaily Retrieved January 25, 2010, from http://www.sciencedaily.com /releases/2007/11/071107074329.htm

58. Bartzokis G, et al. In vivo evaluation of brain iron in Alzheimer’s disease using magnetic resonance imaging. Arch Gen Psychiatry 2000;57:47-53.

59. Joseph JA, et al Grape juice, berries, and walnuts affect brain aging and behavior. J Nutr 2009 Sep;139(9);1813S-7S. [Epub 2009 Jul 29.]

60. Sato Y, et al. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997 Nov;49(5):1273-8.

61. Grant WB. Does vitamin D reduce the risk of dementia? J Alzheimers Dis 2009 May;17(1):151-9.

62. van Praag H. Exercise and the brain: something to chew on. Trends Neurosci 2009 May; 32(5):283-290.

63. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009 Jan;39(1):3-11. [Epub 2008 Jun 23.]

64. Dai Q, et al. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006:119(9):751-9.

Become a Member of Christian Care Ministry and explore the benefits of Medi-Share!